Pfizer drug extends life for people with rare form of lung cancer
Pfizer’s Lorlatinib was tested in a clinical trial of hundreds of people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). | Photo Credit: AFP A Pfizer lung cancer drug has been shown to greatly reduce tumour progression and improve survival outcomes for people in the advanced stages of a rare form of…
Read More “Pfizer drug extends life for people with rare form of lung cancer” »
